Monitoring Quality of Biotherapeutic Products Using Multivariate Data Analysis
- 680 Downloads
Monitoring the quality of pharmaceutical products is a global challenge, heightened by the implications of letting subquality drugs come to the market on public safety. Regulatory agencies do their due diligence at the time of approval as per their prescribed regulations. However, product quality needs to be monitored post-approval as well to ensure patient safety throughout the product life cycle. This is particularly complicated for biotechnology-based therapeutics where seemingly minor changes in process and/or raw material attributes have been shown to have a significant effect on clinical safety and efficacy of the product. This article provides a perspective on the topic of monitoring the quality of biotech therapeutics. In the backdrop of challenges faced by the regulatory agencies, the potential use of multivariate data analysis as a tool for effective monitoring has been proposed. Case studies using data from several insulin biosimilars have been used to illustrate the key concepts.
Keywordsbiosimilars multivariate data analysis process monitoring product quality quality by design
ASR presently serves as the Chairman of the Committee for Advising the Drug Controller General of India on Regulation of Biotech Products. The approach stated in this article does not have any regulatory implications. The article presents merely a scientific perspective.
- 3.Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. The European Medicines Agency Evaluation of Medicines for Human Use. European Medicines Agency. EMEA/CHMP/437/04, UK, 2005.Google Scholar
- 5.Hincal F. An introduction to safety issues in biosimilars/follow-on biopharmaceuticals. J Med CBR Def. 2009;7:1–17.Google Scholar
- 9.International Conference of Harmonisation (2008) ICH Harmonised Tripartite Guideline: Q8(R1) Pharmaceutical Development (http://www.ich.org/LOB/media/MEDIA4986.pdf).
- 10.U.S. Department of Health and Human Services, Food and Drug Administration (2004) Guidance for industry: PAT—a framework for innovative pharmaceutical development, manufacturing and quality assurance (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070305.pdf).
- 11.Guidance for Industry (2008) Q10 Quality Systems Approach to Pharmaceutical CGMP Regulations, ICH Harmonised Tripartite Guideline, Step 4, June.Google Scholar
- 12.U.S. Department of Health and Human Services, Food and Drug Administration (2011) Guidance for industry, process validation: general principles and practices, current good manufacturing practices (CGMP), Revision 1, (http://www.fda.gov/downloads/Drugs/Guidances/UCM070336.pdf).
- 13.WHO Expert Committee on Biological Standardization. (2012). WHO Expert Committee on Biological Standardization: fifty-ninth report. World Health Organization.Google Scholar
- 29.World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.